ABSTRACT
Progression of chronic liver diseases is precipitated by hepatocyte loss, inflammation and fibrosis. This process results in the loss of critical hepatic functions, increasing morbidity and the risk of infection. Medical interventions that treat complications of hepatic failure, including antibiotic administration for systemic infections, impact gut microbiome composition and metabolite production. Using a multi-omics approach on 850 fecal samples from 263 patients with acute or chronic liver disease, we demonstrate that patients hospitalized for liver disease have reduced microbiome diversity and a paucity of bioactive metabolites. We find that patients treated with the orally administered but non-absorbable disaccharide lactulose have increased densities of intestinal Bifidobacteria and reduced incidence of systemic infections and mortality. Bifidobacteria metabolize lactulose, produce high concentrations of acetate and acidify the gut lumen, which, in combination, can reduce the growth of antibiotic-resistant pathobionts such as Vancomycin-resistant Enterococcus faecium. Our studies suggest that lactulose and Bifidobacteria serve as a synbiotic to reduce rates of infection in patients with severe liver disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded privately by the Duchossois Family Institute at the University of Chicago Authors were funded by the National Institutes of Health as follows: T32DK007074 (M.A.O.) U01AA026975 (T.G.C.)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of the University of Chicago gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
In addition to the repositories specified below, all raw data included in the manuscript is publicly available at: https://github.com/yingeddi2008/DFILiverDiseaseMicrobiome. 1. Metagenomic information is publicly available on NCBI under BioProject ID PRJNA912122. 2. Quantitative fecal metabolomic information paired to fecal metagenomic information is publicly available on NCBI under BioProject ID PRJNA912122. 3. Raw data files are publicly available on MetaboLights project ID MTBLS7046.
